Table 1.

Clinical Trials with Targeted Therapies in Patients with Thyroid Cancer

Author and year of the study	Drug	Pathway inhibited	Thyroid cancer	Responses
Gupta-Abramson et al. 2008	Sorafenib	RAF, RET, VEGFR	30 DTC	7 (23%)PR;
				16 (53%)
				SD (DTC)
Kloos et al. 2009	Sorafenib	RAF, RET, VEGFR	41 PTC	6 (15%)PR;
			11 FTC	23 (56%) SD (PTC)
			4 ATC	No response (FTC)
				No response (ATC)
Hoftijzer et al. 2009	Sorafenib	RAF, RET, VEGFR	32 DTC	8 (25%)PR;
				11 (34%)SD (DTC)
Cohen et al. 2008	Sunitinib	E7080, VEGFR	37 DTC	4 (11%)PR; 21 (57%)SD
			6 MTC	(DTC)
				2 (33%)SD (MTC)
Carr et al. 2010	Sunitinib	E7080, VEGFR	28 DTC	1 (3%)CR
			7 MTC	10 (29%)PR
				16 (46%)SD
Cohen et al. 2008	Axitinib	VEGFR, C-KIT, PDGFR	60 pts of any histology	18 (30%)PR, 23 (28%)SD
de Groot 2007	Imatinib	VEGFR 2, RET	15 MTC	4 (27%)SD (MTC)
Wells et al. 2010	Vandetanib	VEGFR 2, EGFR, RET	30 MTC hereditary	6 (20%)PR,
				16 (53%)SD (MTC)
Robinson et al. 2010	Vandetanib	VEGFR 2, EGFR, RET	19 MTC hereditary	3 (16%)PR,
				10 (53%)SD (MTC)
Bible et al. 2010	Pazopanib	VEGFR, PDGFR	39 DeDTC	18 (46%) PR (DeDTC)
Pennel et al. 2008	Gefitinib	EGFR	27 patients of different tumor types	No response

VEGFR = vascular endothelial growth factor receptor; PDGFR = platelet-derived growth factor receptors; EGFR = epidermal growth factor receptor.

DTC = differentiated thyroid cancer; ATC = anaplastic thyroid cancer; PTC = papillary thyroid cancer; FTC = follicular thyroid cancer; DeDTC = dedifferentiated differentiated thyroid cancer; MTC = medullary thyroid carcinoma.

PR = partial response; SD = stable disease; CR = complete response.